2003
DOI: 10.1021/jm030119t
|View full text |Cite
|
Sign up to set email alerts
|

Structure−Activity Relationships of γ-MSH Analogues at the Human Melanocortin MC3, MC4, and MC5 Receptors. Discovery of Highly Selective hMC3R, hMC4R, and hMC5R Analogues

Abstract: It has been shown by extensive studies that melanotropin bioactivities are critically dependent on the core or central tetrapeptide sequence, His-Phe-Arg-Trp, and in alpha-MSH it has been demonstrated further that a reverse-turn type conformation exists at this pharmacophore. To probe the receptor active conformation of the pharmacophore His-Phe-Arg-Trp in gamma-MSH, two different series of gamma-MSH analogues have been designed and synthesized and their biological activities determined at hMC3R, hMC4R, and hM… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
38
0

Year Published

2005
2005
2013
2013

Publication Types

Select...
5
3
1

Relationship

2
7

Authors

Journals

citations
Cited by 24 publications
(38 citation statements)
references
References 36 publications
0
38
0
Order By: Relevance
“…More recently Kavarana et al (39) discovered that another cyclic ␣MSH peptide analog, (O)C-CH2-CH2-c[His6-D-Phe7-Arg8-Trp9-Lys10]amide, was a selective and potent agonist for human MC4R. Furthermore, BalseSchnivasan et al (40) synthesized novel ␣MSH/␤MSH hybrid analogs that led to potent and selective ligands to human MC3R and MC4R. Finally, Oosterom et al (41,42) reported that a major determinant for selective receptor interaction is the conformational presentation of the core sequence in melanocortin peptides directed to the receptor binding pockets of the MC3R and MC4R.…”
Section: Discussionmentioning
confidence: 99%
“…More recently Kavarana et al (39) discovered that another cyclic ␣MSH peptide analog, (O)C-CH2-CH2-c[His6-D-Phe7-Arg8-Trp9-Lys10]amide, was a selective and potent agonist for human MC4R. Furthermore, BalseSchnivasan et al (40) synthesized novel ␣MSH/␤MSH hybrid analogs that led to potent and selective ligands to human MC3R and MC4R. Finally, Oosterom et al (41,42) reported that a major determinant for selective receptor interaction is the conformational presentation of the core sequence in melanocortin peptides directed to the receptor binding pockets of the MC3R and MC4R.…”
Section: Discussionmentioning
confidence: 99%
“…The linear γ-MSH analog 17 , H-Tyr-Val-Nle-Gly-His-Phe-Arg-D-Nal(2′)-Asp-Arg-Phe-Gly-NH 2 (Table 4), was found to be a potent and selective antagonist at the hMC4R [60] while the cyclic Pen 3 -Cys 9 analog 18 also is a potent and selective MC4 antagonist [60], a potent partial agonist at the MC1R and a potent full agonist at the MC5R. The D-Nal(2′)-containing analog 18 , on the other hand, is a potent and selective antagonist at the hMC4R, and a moderate potent agonist at the hMC3R (IC 50 = 150 nM) and a weak antagonist (IC 50 = 1700 nM) at the MC5R [60].…”
Section: Hmc4r Antagonistsmentioning
confidence: 99%
“…The D-Nal(2′)-containing analog 18 , on the other hand, is a potent and selective antagonist at the hMC4R, and a moderate potent agonist at the hMC3R (IC 50 = 150 nM) and a weak antagonist (IC 50 = 1700 nM) at the MC5R [60]. Compound 19 (Table 4) is an interesting cyclic analog related to γ-MSH [45] which, though a modest binder, has highly selective antagonist activity at the MC4R with no binding to the MC1R, MC3R and MC5R.…”
Section: Hmc4r Antagonistsmentioning
confidence: 99%
“…Furthermore, replacement of the oxidizable Met 3 residue with Nle increased the stability of the peptide [52], which is being widely used as a ligand for the hMC3R in a variety of ongoing pharmacological studies and in animal model studies related to the hMC3R. Interestingly, when the Phe 6 residue of γ-MSH was substituted with D-Nal(2′), a substitution known to convert α-MSH analogues to antagonists at the hMC3R and hMC4R [53], the resulting analogue (HTyr-Val-Nle-Gty-His-D-Nal(2′)-Arg-Trp-Asp-Arg-Phe-Gly-NH 2 ) exhibited potent hMC3R/ hMC5R antagonist activity, while retaining potent full agonist activity at the hMC4R [54].…”
Section: Structure-activity Relationships Of Linear Msh-derived Peptidesmentioning
confidence: 99%